These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34742889)

  • 1. Discovery of 3-amino-4-{(3S)-3-[(2-ethoxyethoxy)methyl]piperidin-1-yl}thieno[2,3-b]pyridine-2-carboxamide (DS96432529): A potent and orally active bone anabolic agent.
    Saito K; Shinozuka T; Nakao A; Kunikata T; Nakai D; Nagai Y; Naito S
    Bioorg Med Chem Lett; 2021 Dec; 54():128440. PubMed ID: 34742889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and structure-activity relationship of thienopyridine derivatives as bone anabolic agents.
    Saito K; Nakao A; Shinozuka T; Shimada K; Matsui S; Oizumi K; Yano K; Ohata K; Nakai D; Nagai Y; Naito S
    Bioorg Med Chem; 2013 Apr; 21(7):1628-42. PubMed ID: 23453217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationship of 4-alkoxy-thieno[2,3-b]pyridine derivatives as potent alkaline phosphatase enhancers for osteoporosis treatment.
    Saito K; Shinozuka T; Nakao A; Kiho T; Kunikata T; Shiiki T; Nagai Y; Naito S
    Bioorg Med Chem Lett; 2019 Jul; 29(14):1769-1773. PubMed ID: 31101474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzofuran-pyran hybrids: A new class of potential bone anabolic agents.
    Gupta S; Adhikary S; Modukuri RK; Choudhary D; Trivedi R; Sashidhara KV
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1719-1724. PubMed ID: 29703629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of coumarin-dihydropyridine hybrids as bone anabolic agents.
    Sashidhara KV; Kumar M; Khedgikar V; Kushwaha P; Modukuri RK; Kumar A; Gautam J; Singh D; Sridhar B; Trivedi R
    J Med Chem; 2013 Jan; 56(1):109-22. PubMed ID: 23214410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists.
    Didiuk MT; Griffith DA; Benbow JW; Liu KK; Walker DP; Bi FC; Morris J; Guzman-Perez A; Gao H; Bechle BM; Kelley RM; Yang X; Dirico K; Ahmed S; Hungerford W; DiBrinno J; Zawistoski MP; Bagley SW; Li J; Zeng Y; Santucci S; Oliver R; Corbett M; Olson T; Chen C; Li M; Paralkar VM; Riccardi KA; Healy DR; Kalgutkar AS; Maurer TS; Nguyen HT; Frederick KS
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4555-9. PubMed ID: 19625189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anabolic effects of PTH and the 'anabolic window'.
    Pazianas M
    Trends Endocrinol Metab; 2015 Mar; 26(3):111-3. PubMed ID: 25662368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tryptophan hydroxylase 1 (Tph-1)-targeted bone anabolic agents for osteoporosis.
    Fu HJ; Zhou YR; Bao BH; Jia MX; Zhao Y; Zhang L; Li JX; He HL; Zhou XM
    J Med Chem; 2014 Jun; 57(11):4692-709. PubMed ID: 24844139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone.
    Kostenuik PJ; Ferrari S; Pierroz D; Bouxsein M; Morony S; Warmington KS; Adamu S; Geng Z; Grisanti M; Shalhoub V; Martin S; Biddlecome G; Shimamoto G; Boone T; Shen V; Lacey D
    J Bone Miner Res; 2007 Oct; 22(10):1534-47. PubMed ID: 17576164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure activity relationship study on the peptide hormone preptin, a novel bone-anabolic agent for the treatment of osteoporosis.
    Amso Z; Kowalczyk R; Watson M; Park YE; Callon KE; Musson DS; Cornish J; Brimble MA
    Org Biomol Chem; 2016 Oct; 14(39):9225-9238. PubMed ID: 27488745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzofuran-dihydropyridine hybrids: A new class of potential bone anabolic agents.
    Modukuri RK; Choudhary D; Gupta S; Rao KB; Adhikary S; Sharma T; Siddiqi MI; Trivedi R; Sashidhara KV
    Bioorg Med Chem; 2017 Dec; 25(24):6450-6466. PubMed ID: 29097030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anabolic agents and bone quality.
    Sibai T; Morgan EF; Einhorn TA
    Clin Orthop Relat Res; 2011 Aug; 469(8):2215-24. PubMed ID: 21132409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgenic-anabolic activities of some new synthesized steroidal pyrane, pyridine and thiopyrimidine derivatives.
    Abdalla MM; Amr Ael-G; Al-Omar MA; Hussain AA; Amer MS
    Bioorg Khim; 2014; 40(5):618-28. PubMed ID: 25895357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel and potent calcium-sensing receptor antagonists: discovery of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate (TAK-075) as an orally active bone anabolic agent.
    Yoshida M; Mori A; Morimoto S; Kotani E; Oka M; Notoya K; Makino H; Ono M; Shirasaki M; Tada N; Fujita H; Ban J; Ikeda Y; Kawamoto T; Goto M; Kimura H; Baba A; Yasuma T
    Bioorg Med Chem; 2011 Mar; 19(6):1881-94. PubMed ID: 21353570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withaferin A: a proteasomal inhibitor promotes healing after injury and exerts anabolic effect on osteoporotic bone.
    Khedgikar V; Kushwaha P; Gautam J; Verma A; Changkija B; Kumar A; Sharma S; Nagar GK; Singh D; Trivedi PK; Sangwan NS; Mishra PR; Trivedi R
    Cell Death Dis; 2013 Aug; 4(8):e778. PubMed ID: 23969857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of bone anabolic agents on bone ultrastructure.
    Cortet B
    Osteoporos Int; 2009 Jun; 20(6):1097-100. PubMed ID: 19340503
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans.
    Aslan D; Andersen MD; Gede LB; de Franca TK; Jørgensen SR; Schwarz P; Jørgensen NR
    Scand J Clin Lab Invest; 2012 Feb; 72(1):14-22. PubMed ID: 22085136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats.
    McManus JF; Davey RA; Maclean HE; Doust EA; Chiu WS; Sims NA; Bouxsein ML; Glatt V; Zajac JD; Danks JA
    Bone; 2008 Jun; 42(6):1164-74. PubMed ID: 18387351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Black bear parathyroid hormone has greater anabolic effects on trabecular bone in dystrophin-deficient mice than in wild type mice.
    Gray SK; McGee-Lawrence ME; Sanders JL; Condon KW; Tsai CJ; Donahue SW
    Bone; 2012 Sep; 51(3):578-85. PubMed ID: 22584007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.